Advertisement
Screener

GLAUKOS Corp (GKOS) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

GLAUKOS Corp Research and Development Expense

GLAUKOS Corp (GKOS) reported Research and Development Expense of $26.88 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2022-05-05

  • GLAUKOS Corp research and development expense for the quarter ending 2022-03-31 was $26.88M, a 26.66% increase year-over-year.
  • GLAUKOS Corp research and development expense for the quarter ending 2021-03-31 was $21.22M.
  • GLAUKOS Corp research and development expense for the quarter ending 2019-03-31 was $13.93M, a 27.73% increase year-over-year.
  • GLAUKOS Corp research and development expense for the quarter ending 2018-12-31 was $12.96M, a 23.11% increase year-over-year.
  • GLAUKOS Corp research and development expense for fiscal 2018 was $49.68M, a 27.69% increase from fiscal 2017.
  • GLAUKOS Corp research and development expense for fiscal 2017 was $38.91M, a 33.13% increase from fiscal 2016.
  • GLAUKOS Corp research and development expense for fiscal 2016 was $29.22M, a 16.67% increase from fiscal 2015.
  • GLAUKOS Corp research and development expense for fiscal 2015 was $25.05M, a 30.42% increase from fiscal 2014.
Period endResearch and Development Expense 3 monthResearch and Development Expense 6 monthResearch and Development Expense 9 monthResearch and Development Expense 12 month
2022-03-31$26.88M
10-Q · filed 2022-05-05
2021-03-31$21.22M
10-Q · filed 2022-05-05
2019-03-31$13.93M
10-Q · filed 2019-05-08
$26.89M
derived: sum of 2 quarters · filed 2019-05-08
$40.09M
derived: sum of 3 quarters · filed 2019-05-08
$52.70M
derived: sum of 4 quarters · filed 2019-05-08
2018-12-31$12.96M
10-K · filed 2019-02-28
$26.16M
derived: sum of 2 quarters · filed 2019-02-28
$38.77M
derived: sum of 3 quarters · filed 2019-02-28
$49.68M
10-K · filed 2019-02-28
2018-09-30$13.20M
10-K · filed 2019-02-28
$25.81M
derived: sum of 2 quarters · filed 2019-02-28
$36.72M
derived: sum of 3 quarters · filed 2019-05-08
$47.24M
derived: sum of 4 quarters · filed 2019-05-08
2018-06-30$12.61M
10-K · filed 2019-02-28
$23.52M
derived: sum of 2 quarters · filed 2019-05-08
$34.04M
derived: sum of 3 quarters · filed 2019-05-08
$43.85M
derived: sum of 4 quarters · filed 2019-05-08
2018-03-31$10.91M
10-Q · filed 2019-05-08
$21.43M
derived: sum of 2 quarters · filed 2019-05-08
$31.24M
derived: sum of 3 quarters · filed 2019-05-08
$40.87M
derived: sum of 4 quarters · filed 2019-05-08
2017-12-31$10.53M
10-K · filed 2019-02-28
$20.33M
derived: sum of 2 quarters · filed 2019-02-28
$29.96M
derived: sum of 3 quarters · filed 2019-02-28
$38.91M
10-K · filed 2019-02-28
2017-09-30$9.80M
10-K · filed 2019-02-28
$19.44M
derived: sum of 2 quarters · filed 2019-02-28
$28.38M
derived: sum of 3 quarters · filed 2019-02-28
$35.78M
derived: sum of 4 quarters · filed 2019-02-28
2017-06-30$9.63M
10-K · filed 2019-02-28
$18.57M
derived: sum of 2 quarters · filed 2019-02-28
$25.97M
derived: sum of 3 quarters · filed 2019-02-28
$33.78M
derived: sum of 4 quarters · filed 2019-02-28
2017-03-31$8.94M
10-K · filed 2019-02-28
$16.34M
derived: sum of 2 quarters · filed 2019-02-28
$24.15M
derived: sum of 3 quarters · filed 2019-02-28
$31.10M
derived: sum of 4 quarters · filed 2019-02-28
2016-12-31$7.40M
10-K · filed 2018-02-28
$15.21M
derived: sum of 2 quarters · filed 2018-02-28
$22.16M
derived: sum of 3 quarters · filed 2018-02-28
$29.22M
10-K · filed 2019-02-28
2016-09-30$7.81M
10-K · filed 2018-02-28
$14.76M
derived: sum of 2 quarters · filed 2018-02-28
$21.82M
10-Q · filed 2016-11-14
$28.12M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$6.96M
10-K · filed 2018-02-28
$14.02M
10-Q · filed 2016-08-04
$20.31M
derived: sum of 3 quarters · filed 2018-02-28
$26.48M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$7.06M
10-K · filed 2018-02-28
$13.36M
derived: sum of 2 quarters · filed 2018-02-28
$19.53M
derived: sum of 3 quarters · filed 2018-02-28
$26.87M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$6.29M
10-K · filed 2017-03-15
$12.47M
derived: sum of 2 quarters · filed 2017-03-15
$19.81M
derived: sum of 3 quarters · filed 2017-03-15
$25.05M
10-K · filed 2018-02-28
2015-09-30$6.17M
10-K · filed 2017-03-15
$13.51M
derived: sum of 2 quarters · filed 2017-03-15
$18.75M
10-Q · filed 2016-11-14
$24.06M
derived: sum of 4 quarters · filed 2017-03-15
2015-06-30$7.34M
10-K · filed 2017-03-15
$12.58M
10-Q · filed 2016-08-04
$17.89M
derived: sum of 3 quarters · filed 2017-03-15
$22.98M
derived: sum of 4 quarters · filed 2017-03-15
2015-03-31$5.24M
10-K · filed 2017-03-15
$10.55M
derived: sum of 2 quarters · filed 2017-03-15
$15.64M
derived: sum of 3 quarters · filed 2017-03-15
$20.06M
derived: sum of 4 quarters · filed 2017-03-15
2014-12-31$5.31M
10-K · filed 2016-03-15
$10.40M
derived: sum of 2 quarters · filed 2016-03-15
$14.82M
derived: sum of 3 quarters · filed 2016-03-15
$19.20M
10-K · filed 2017-03-15
2014-09-30$5.09M
10-K · filed 2016-03-15
$9.52M
derived: sum of 2 quarters · filed 2016-03-15
$13.90M
10-Q · filed 2015-11-12
2014-06-30$4.42M
10-K · filed 2016-03-15
$8.80M
10-Q · filed 2015-08-13
2014-03-31$4.38M
10-K · filed 2016-03-15
2013-12-31$15.51M
10-K · filed 2016-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSULET CORP (PODD)United States$9.420B28.12
GLOBUS MEDICAL INC (GMED)United States$9.977B20.03
BAXTER INTERNATIONAL INC (BAX)United States$12.139B-10.35
MiniMed Group, Inc. (MMED)United States$5.748B-16.85
Penumbra Inc (PEN)United States$12.596B77.33
MERIT MEDICAL SYSTEMS INC (MMSI)United States$5.212B28.44
TELEFLEX INC (TFX)United States$5.093B-5.44
HAEMONETICS CORP (HAE)United States$4.821B36.52
Heartflow, Inc. (HTFL)United States$4.225B
ICU MEDICAL INC/DE (ICUI)United States$4.153B18.85